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98Clinical presentation and outcome after failed
infrainguinal endovascular and open
revascularization in patients with chronic
limb ischemia
Hasan H. Dosluoglu, MD,a,b Purandath Lall, MBBS,a,b Raphael Blochle, MD,b Linda M. Harris, MD,b
and Maciej L. Dryjski, MD,b Buffalo, NY
Objective: Failure of prior endovascular (EV) interventions for chronic limb ischemia has been reported to negatively affect
patency and limb salvage after subsequent revascularization procedures. The goal of our study was to compare the clinical
presentation of patients who failed infrainguinal EV and open revascularizations (OR) and the effect of the initial
intervention on ﬁnal outcomes.
Methods: From June 2001 to October 2010, 216 patients (237 limbs; 66 disabling claudication [DC], 171 critical limb
ischemia [CLI]) presented with failed infrainguinal OR or EV revascularization for chronic limb ischemia. Clinical
presentation, reinterventions, patency and limb salvage rates, and ﬁnal outcomes were analyzed.
Results: TheEVgroup (n[ 143) hadmore diabetes (44% vs 57%;P[ .048) and ulcers (26% vs 38%;P[ .039), whereas the
OR group (n[ 94) had more multilevel revascularizations (59% vs 33%; P < .001), rest pain (23% vs 9%; P[ .002), and
infrapopliteal interventions (58% vs 38%; P[ .038). Presentation at time of failure was non-limb-threatening ischemia in
70% of DC and 16% of CLI patients (P < .001), with no difference in those initially treated with EV or OR. In CLI, 23%
presented with acute limb ischemia in theOR group vs 10% in the EV group (P[ .024). Early failure (<3months) occurred
in 15% of DC and in 36% of CLI patients and was more in the OR than in the EV group (30% vs 7% for DC [P[ .011] and
71% vs 38% forCLI [P[ .024]). Overall, 195 (82%) had attempted reinterventions (79% inDC and 85% inCLI;P[ .245).
In DC patients, 48% of OR had ORD EV and 26% had EV; 32% of EV had ORD EV and 47% had EV reinterventions. In
CLI patients, 40% of OR had OR D EV and 42% had EV; 17% of EV had OR D EV; and 70% had EV reinterventions.
A patent revascularized limbwas achieved in 66%ofOR and in 92%of EVpatients (P < .001). Patency and limb salvagewere
signiﬁcantly better in the EV group, mainly due to the difference in CLI patients, whereas survival was identical.
Conclusions: Clinical presentation after failed infrainguinal revascularization is determined by the initial indication. CLI
patients are more likely to present early with acute limb ischemia, especially after OR. EV reinterventions play a signiﬁcant
role in the management of patients with failed revascularization, and EV failure is associated with better outcomes than
those after OR failure, likely due to OR patients having more disadvantaged anatomy and advanced disease at the time of
their initial presentation. (J Vasc Surg 2013;58:98-104.)Endovascular (EV) intervention (EVI) has been largely
adopted as the ﬁrst-line treatment of symptomatic chronic
limb ischemia, even in those with complex anatomy;
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://dx.doi.org/10.1016/j.jvs.2012.12.076after bypass procedures to rescue a failed EVI raised the issue
of bypass as the primary revascularization, especially in those
with a high risk of failure. Exact reasons for poorer outcomes
after failure are not known but have been hypothesized to
include loss of collateral vessels and runoff vessels due to
embolization or wire or catheter injury or a more distal re-
entry point resulting in loss of patent arteries.1-3
In the Bypass versus Angioplasty in Severe Ischaemia of
the Leg (BASIL) trial, patients undergoing bypass after
a failed angioplasty had a worse amputation-free survival
(AFS) than those undergoing primary bypass.4 More
recently, Nolan et al5 found that 1-year ipsilateral amputa-
tion and graft occlusion rates were worse in patients with
prior EVI. Although outcomes in prior EVI were similar
to previous bypass failures, they concluded that patients
who are eligible for either procedure might beneﬁt from
bypass. However, these poor outcomes may simply be
the result of selecting higher-risk patients with disadvan-
taged anatomy and presentation. Other reports suggest
that most reinterventions after failure of EVI can be treated
percutaneously, and the level of amputation, distal bypass,
and ﬁnal outcomes are not affected.6,7
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presentation of patients whose infrainguinal EV and open
revascularizations (OR) failed and to see the type of effect
the initial intervention had on ﬁnal outcomes.METHODS
The Institutional Review Board approved this study.
Design and methodology. All patients who presented
to theVeterans AffairsWesternNewYorkHealthcare System
between May 21, 2001, and October 31, 2010, with symp-
tomatic chronic limb ischemia (Rutherford category 3-6)
and underwent infrainguinal EVI or OR were screened to
identify those whose procedure failed. These patients were
retrospectively analyzed from our prospectively maintained
database. Comparisons were made between those who pre-
sented after failing EVI (EV group) and OR (OR group).
Demographics, comorbidities, clinical presentation, nonin-
vasive arterial studies, other imaging studies, procedural
details, the most distal level of intervention (femoropopliteal
or infrapopliteal), TransAtlantic Inter-Society Consensus
Statement (TASC) classiﬁcation,8,9 postoperative course,
follow-up arterial studies, and condition on last follow-up
were recorded.
All patients were monitored postoperatively and at 3,
6, and every 6 months thereafter for ankle-brachial index
(ABI) measurements and graft or stent velocities. Patients
with refractory wounds, return of symptoms, or signiﬁcant
change of ABI or pulse volume recordings with suspicion
of failing graft or EV-treated segment underwent angi-
ography. Reinterventions were performed to maintain
patency or when clinically indicated.
Deﬁnitions. Primary and secondary patency rates were
deﬁned as in reporting standards, with the time of presen-
tation with failure as time “0.”10 We deﬁned tertiary
patency as the entire period with a patent revascularization
(bypass graft or EV), although the concept was deﬁned for
bypass procedures.10,11 Multilevel reconstruction was
deﬁned as at least two levels of intervention. The level of
intervention was classiﬁed as femoropopliteal or infrapo-
pliteal, based on the most distal level of intervention. The
loss of patency was deﬁned as occlusion, >70% restenosis,
an elevated ratio of velocity to the proximal segment being
>300% by duplex examination, loss of a previously palpable
pulse, dampened pulse volume recordings, or decrease in
ABI of >0.2. Patients were considered to be non-
ambulatory when they were wheelchair-bound, could only
transfer, or were bedridden. Major amputation was deﬁned
as a supramalleolar amputation.
Procedures. Our approach to revascularization at the
time of initial presentation has been described elsewhere.12
All procedures were performed by vascular surgeons. We
used the EV-ﬁrst approach since 2002. The list of opera-
tions is reported in Table I (online only).
Depending on presentation at the time of failure (emer-
gent/urgent/elective), patients were scheduled for an
angiogram. The type of reintervention (thrombolysis, EV,
or OR) was decided at the time of angiography. Patientswith acute limb ischemia (ALI) were therapeutically hepa-
rinized until intervention.
For patients without occluded EV-treated arteries, the
stenosed segments were treated with plain or cutting-
balloon angioplasty with prolonged inﬂation times. Athe-
rectomy was performed in a few patients. For patients
who had patent grafts, balloon angioplasty using plain or
cutting balloons, or surgical patch angioplasty, was per-
formed after failure of balloon angioplasty. In patients
who presented with occlusion, AngioJet (Medrad Inc, War-
rendale, Pa) thrombectomy was performed with selective
use of embolic protection (ﬁlter), with additional thrombol-
ysis when needed. After thrombus removal, the underlying
pathology was treated. For occluded grafts, thrombectomy
was followed by thrombolysis and surgical revision or angio-
plasty. Patients who had EV reinterventions for EV failure
were given lifelong clopidogrel (75 mg) and enteric-coated
acetyl salicylic acid (ECASA; 81 mg). Patients who had
recanalized bypass grafts were prescribed warfarin. Patients
already receiving warfarin were prescribed adjunctive
ECASA or clopidogrel.
Statistical analysis. Data analysis was performed using
SPSS 18.0 software (SPSS Inc, Chicago, Ill). Society for
Vascular Surgery reporting standards for lower extremity
arterial procedures were followed.10 Kaplan-Meier anal-
ysis and the log-rank test were used to compare groups for
primary, secondary, and tertiary patency, limb salvage,
amputation-free survival (AFS), and overall survival. AFS
and survival were based on patients and limb salvage, and
patency rates were based on limbs. Continuous variables
are given as mean 6 standard deviation. Demographic
comparisons were made using the c2 test for categoric
variables and by t-test for continuous variables.
RESULTS
Of the 794 patients (992 limbs, 99% males) who under-
went revascularization, the initial intervention failed in 216
patients (237 limbs); 127 patients (143 limbs) had EVI,
and 89 patients (94 limbs) had OR. The EV group consti-
tuted 20.6% of EV-treated patients, and the OR group
constituted 31.5% of OR-treated patients. Demographic
and preoperative characteristics of patients and the level of
interventions are summarized in Table II. The EV group
had more patients with diabetes (57% vs 44%; P ¼ .048)
and ischemic ulcers (38% vs 26%; P ¼ .039), and the OR
group had more patients with rest pain (23% vs 9%; P ¼
.002) andmore multilevel (59% vs 33%; P< .001) and infra-
popliteal (52% vs 38%; P ¼ .038) revascularizations. In the
EV group, 100 had CLI at the initial presentation (69.9%)
compared with 71 (75.5%) in the OR group (P ¼ .347).
The TASC classiﬁcation was A in 8%, B in 7%, C in 27%,
and D in 57% in the EV group and B in 1%, C in 3%, and
D in 96% in the OR group.
The ABIs in patients who were initially treated for DC
were similar in the EV and OR groups preoperatively
(0.57 6 0.21 vs 0.48 6 0.18; P ¼ .077) and postopera-
tively (0.93 6 0.14 vs 0.9 6 0.12; P ¼ .531). ABIs were
also similar in EV and OR patients treated for CLI
Table II. Demographic characteristics, comorbidities,
and presenting symptoms of patients
Variablesa
Patient-based
data
All
(N ¼ 216)
OR
(n ¼ 89)
EV
(n ¼ 127) P
Age, years 67.6 6 10.4 67.3 6 10.3 67.7 6 10.4 .772
CAD 54 58 51 .239
Hypertension 73 44 57 .474
Diabetes mellitus 52 44 57 .048
CVD 14 13 14 .885
Hyperlipidemia 67 66 68 .826
COPD 21 21 21 .988
Nonambulatory 14 16 13 .512
Statin 58 61 56 .168
Albumin, g/dL 3.5 6 0.6 3.5 6 0.6 3.5 6 0.6 .966
Limb-based data (N ¼ 237) (n ¼ 94) (n ¼ 143)
Indication
Claudication 28 24 30 .347
Rest pain 15 23 9 .002
Ulcer 33 26 38 .039
Gangrene 24 27 22 .457
Multilevel 43 60 33 <.001
Femoropopliteal 56 48 62 .038
Infrapopliteal 44 52 38 .038
CAD,Coronary artery disease;COPD, chronic obstructive pulmonary disease;
CVD, cerebrovascular disease; EV, endovascular; OR, open revascularization.
aContinuous data are shown as mean 6 standard deviation and categoric
data as percentage.
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postoperatively (0.86 6 0.16 vs 0.84 6 0.18; P ¼ .454).
The number of patent runoff vessels after revascularization
was similar in patients initially treated for DC in EV vs OR
(2.1 6 0.7 vs 1.8 6 0.8; P ¼ .114) and for CLI (1.5 6 0.7
vs 1.7 6 0.8; P ¼ .125).
The mode of presentation at failure by initial presenta-
tion (CLI or DC) in the OR and EV groups are reported in
Table III. At the time of failure, 5% of DC and CLI
patients were asymptomatic, 64% of patients initially
treated for DC, 11% of CLI patients presented with claudi-
cation (P < .001), and 84% of CLI patients presented
with limb-threatening ischemia. Most CLI and DC
patients presented with nonacute ischemia; however, CLI
patients who had OR were more likely to present with
ALI than those who had EV (23% vs 10%; P ¼ .024).
The procedure was more likely to fail in patients treated
for DC >3 months after the initial procedure than CLI
patients (85% vs 64%; P ¼ .002), but the procedure in
OR patients was more likely to fail <3 months compared
with EV patients, especially with CLI (71% of failures in
CLI vs 38% in EV; P ¼ .024).
Failure after the initial revascularization occurred early
(<3 months) in 72 limbs (30%) and was similar in the OR
and EV groups (33% vs 28%; Table IV). There was no
difference in early and late failure in patients who were
asymptomatic (3% vs 6%; P ¼ .355), but acute presentation
was more common in the early group (22% vs 10%; P ¼
.023), especially in those with early failure after an OR(32% vs 15%; P ¼ .092). Patients with early failures were
more likely to present with limb-threatening ischemia
than late failures (86% vs 62%; P < .001), with no differ-
ence between EV and OR groups. In the OR group who
had CLI, 10 of the 34 patients who had polytetraﬂuoro-
ethylene graft failures, 4 of the 7 patients who had cryopre-
served vein graft failures, and 10 of the 27 patients who had
autologous graft failures occurred #3 months. The four
cryopreserved graft failures were due to graft occlusions
and resulted in amputations. Eight of the 10 polytetra-
ﬂuoroethylene early failures were distal bypasses, seven of
whom had occluded grafts, and eight had major amputa-
tions. The autologous vein graft early failures were due
to occlusions in only three, and seven had patent grafts at
the time of failure; ﬁve patients had amputations, three of
whom had patent grafts.
Two patients in the OR group who had CLI initially
underwent above- and below-knee amputations at the
time of failure (Table V). In the OR group, new bypass
was performed in 16% and open revision in 15%, with or
without Fogarty thrombectomy. Three patients required
graft removal due to infection, one of whom remained
asymptomatic, and two eventually required above-knee
amputations. EVIs were performed in 46%, alone in 27%
or as an adjunct to AngioJet thrombectomy, with or without
thrombolysis in 19%. No intervention was performed for the
remaining 20%. In the EV group, 8% had a new bypass, and
76% had EVI alone (58%) or as an adjunct to AngioJet
thrombectomy, with or without thrombolysis (18%). The
remaining 16% had no interventions.
Overall, maintenance of patency of the initial revascu-
larization was attempted in 166 limbs (70%), 61% in the
OR group and 76% in the EV group (P ¼ .01). This differ-
ence was due to the results in the patients with CLI, which
were 63% in the OR group and 82% in EV group (P ¼
.006), whereas results in patients with DC were 52% for
the OR and 63% for the EV groups (P ¼ .403). Initial
success of restoring patency of the initial revascularization
was 46% in the OR and 62% in the EV groups (P ¼
.038). Any revascularization was attempted in 195 limbs
(82%), comprising 79% in the OR and 85% in the EV
groups (P ¼ .245). Patency was achieved in 66% in the
OR group in whom revascularization was attempted vs
92% in EV patients (P < .001). In patients with DC,
76% had any revascularization attempt (OR, 70%; EV,
79%; P ¼ .391), and 85% of patients with CLI had any
revascularization attempt (OR, 80%; EV, 87%; P ¼ .341).
Eventually, patency of the initial revascularization could
not be achieved in 43% in the OR group and in 23% in
the EV group (P ¼ .001).
The mean follow-up was 41.2 6 25.5 months (range,
2-115 months) after the index procedure and 28.5 6 21.4
months (range, 0-104 months) after the ﬁrst reintervention
or diagnosis of failure. The mean number of reinterven-
tions were 1.1 6 0.8 (range, 0-3) in the OR group and
1.2 6 0.8 (range, 0-5) in the EV group. In the 66 DC
patients, 35% of OR had bypass or open revision,
13% had OR þ EV, 26% had EV, and 26% had no
Table IV. Early vs late presentations on type of presentation
Variable Overall, No. (%)
Early (n ¼ 72) Late (n ¼ 165)
OR (n ¼ 31),
No. (%)
EV (n ¼ 41),
No. (%)
OR (n ¼ 63),
No. (%)
EV (n ¼ 102),
No. (%)
Asymptomatic 1 (3) 1 (2) 3 (5) 7 (7)
12 (5) 2 (3) 10 (6)
Limb threatening 26 (84) 36 (88) 43 (68) 59 (58)
164 (69) 62 (86) 102 (62)a
Acute 10 (32) 6 (15)b 8 (13) 9 (9)
33 (14) 16 (22) 17 (10)c
EV, Endovascular; OR, open revascularization.
aP < .001, late vs early.
bP ¼ .092, early OR vs EV.
cP ¼ .023, late vs early.
Table III. Presentation modes of patients by the type of initial presentation of critical limb ischemia (CLI) or disabling
claudication (DC) in open revascularization (OR) and endovascular (EV) groups
Variables
Overall limbs
(N ¼ 237), No. (%)
DC (n ¼ 66) CLI (n ¼ 171)
OR (n ¼ 23),
No. (%)
EV (n ¼ 43),
No. (%)
OR (n ¼ 71),
No. (%)
EV (n ¼ 100),
No. (%)
Asymptomatic 1 (4) 2 (5) 3 (4) 6 (6)
12 (5) 3 (5) 9 (5)
Claudication 13 (57) 29 (67) 7 (10) 11 (11)
60 (25) 42 (64) 18 (11)a
Limb threatening 9 (39) 12 (28) 61 (86) 83 (83)
165 (70) 21 (32) 144 (84)b
Acute 2 (8) 5 (12) 16 (23) 10 (10)c
33 (14) 7 (11) 26 (15)
Early 7 (30) 3 (7)d 24 (71) 38 (38)e
72 (30) 10 (15) 62 (36)f
aP < .001, CLI vs DC.
bP < .001, CLI vs DC.
cP ¼ .024, EV vs OR, in CLI.
dP ¼ .011, EV vs OR, in DC.
eP ¼ .024, EV vs OR, in CLI.
fP ¼ .002, CLI vs DC.
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OR þ EV, 47% had EV reinterventions, and the remaining
21% had no reinterventions. No amputations were per-
formed at the time of failure. In CLI patients, 32% of
OR had bypass or OR revisions, 8% had OR þ EV, 42%
had EV, and 17% had no reinterventions; 3% of the EV
group had bypass, 14% had bypass þ EV interventions,
70% had EV reinterventions, and 13% had no reinterven-
tions. The two amputations at the time of failure occurred
in the OR group. In the CLI patients, bypass or open
thrombectomy was performed in signiﬁcantly more OR
patients (32% vs 3%; P < .001), and EV reinterventions
only were performed signiﬁcantly more in patients in the
EV group (70% vs 42%; P < .001; Table VI).
The primary patency rates at 12, 24, and 36 months
after reintervention were 47% 6 7%, 44% 6 8%, and
26% 6 9% in the OR group (n ¼ 57) and 71% 6 5%,
56% 6 6%, and 54% 6 6% in the EV group (n ¼ 109;
P ¼ .001). The secondary patency rates at 12, 24 and36 months after reintervention were 54% 6 7%, 50% 6
8%, and 30% 6 10% in the OR group and 84% 6 4%,
75% 6 5%, and 72% 6 6% in the EV group (P < .001),
and the respective tertiary patency rates after reintervention
were 75% 6 5%, 69% 6 6%, and 59% 6 8% in the OR
group (n ¼ 74) and 94% 6 2%, 93% 6 3%, and 91% 6
3% in the EV group (n ¼ 121; P < .001). When all patients
were included, the tertiary patency rates after the index
revascularization procedure at 12, 24 and 36 months
were 60% 6 5%, 55% 6 6%, and 47% 6 7% in the OR
group (n ¼ 94) and 80% 6 4%, 78% 6 4%, and 77% 6
4% in EV group (n ¼ 143; P < .001).
In the 171 patients with CLI, limb salvage rates at 12,
24, and 36 months were 55% 6 6%, 53% 6 6%, and 53% 6
6% in OR group (n ¼ 71) and 83% 6 4%, 77% 6 5%, and
71%6 6% (P< .001) in the EV group (n ¼ 100). The limb
salvage rates at 36 months in DC patients were 89% 6 9%
in the OR group (n ¼ 23) and 100% in the EV group
(n ¼ 43; P ¼ .086). The survival rates at 60 months
Table V. Procedures performed at the time of
presentation with failure
Variable
OR (n ¼ 94),
No. (%)
EV (n ¼ 143),
No. (%)
New bypass 15 (16) 11 (8)
Open revision 6 Fogarty 12 (15) 0 (0)
Graft removal (infection) 3 (3) 0 (0)
EV interventions 43 (46) 109 (76)
AngioJet 6 lysis 18 (19) 26 (18 )
EV alone 25 (27) 83 (58)
AKA/BKA 2 (2) 0 (0)
No intervention 19 (20) 23 (16)
AKA, Above-knee amputation; BKA, below-knee amputation; EV, endo-
vascular; OR, open revascularization.
JOURNAL OF VASCULAR SURGERY
102 Dosluoglu et al July 2013were similar, at 56% 6 6% in the OR group and 58% 6 6%
in the EV group (P ¼ .832).
Overall, 27 patients in the OR group and 31 patients
in the EV group had a new bypass. In the DC group,
two amputations occurred in OR patients, at 32 and
100 months after the initial procedure, one due to graft
infection and the other due to severe diabetic foot infec-
tion. In the CLI group, 19 patients in the OR group had
new bypass grafts and six eventually needed major amputa-
tions (32%), whereas in the EV group, 17 patients had
a new bypass, with three (18%) eventual major amputations
(P ¼ .335 vs OR group).
In patients in the EV group who initially had DC,
TASC II classiﬁcation of the initial treated segment did
not affect the mode of failure at presentation, and there
was no difference between the EV TASC C/D group
and the OR groups (Table VII). However, in patients
who were initially treated for CLI, 95% of patients in the
A/B group presented with tissue loss vs 61% in the C/D
group (P ¼ .011) and 45% in the OR group (P < .001),
whereas 23% of patients in the OR group presented with
ALI vs 0% in the A/B group (P ¼ .036) and 12% in
the C/D group (P ¼ .146 vs A/B and P ¼ .078 vs
OR; Table VII). Bypass was more likely in patients in the
C/D group than in the A/B group (19% vs 0%; P ¼
.057), but the OR group had the highest new bypass rate
(44%; P ¼ .001 vs A/B and C/D). Major amputation
occurred in 25% of the A/B group and in 19% in the
C/D group, and 46% in the OR group (P < .001 vs C/
D). In the EV-treated patients, seven (23%) of the 31
patients who required bypass needed a more distal bypass
(1 TASC B, 3 TASC C, and 3 TASC D), whereas the
bypass was more proximal in two patients (6%), and none
had major amputations. The three amputations occurred
in patients who had distal bypasses unaffected by the EV
procedure. One patient had embolization during the initial
intervention and needed thrombolysis, and amputation
resulted 15 months later when the graft occluded. Overall
patency of bypasses at 36 months after EV failure (n ¼ 31)
was similar to the patency of second bypasses in the OR
group (n ¼ 27; 74% 6 9.5% vs 81% 6 8%; P ¼ .279), as
was limb salvage (80% 6 8% vs 90% 6 5%; P ¼ .268).DISCUSSION
With the wide adoption of increasingly complex EVIs
for patients with CLI, including those with complex
anatomy, the issue regarding when to choose bypass over
advanced EV techniques becomes more difﬁcult, especially
considering that the TASC recommendations are often not
followed, mostly due to patient comorbidities. Several
studies suggested that EVI failure resulted in poorer patient
outcomes after bypass than in those who had bypass before
any intervention.1-3 The strongest data supporting this issue
came from the BASIL trial,4 in which outcomes of 37
patients who underwent bypass after balloon angioplasty
were compared with 184 patients who had initial bypass,
and the AFS at 12 months was signiﬁcantly better in the
initial bypass group (70% vs 40%; P ¼ .006). Although
some small single-center series reported loss of runoff vessels,
increased amputation, or more complex bypass proce-
dures,1-3 others have suggested that most of these failures
can bemanaged percutaneously and that there was no signif-
icant effect on amputation rates or other outcomes.6,7
Nolan et al5 analyzed 1880 patients who had lower
extremity bypasses for CLI between 2003 and 2009 in
the Vascular Study Group of New England Study Group
and found the 1-year major amputation and graft occlusion
rates were signiﬁcantly higher in patients who had prior
ipsilateral peripheral EVI (31% vs 20%; P ¼ .046) than
those without (28% vs 18%; P ¼ .009). They reported
that patients with previous bypasses also had poorer
outcomes, with 1-year major amputation of 29% vs 20%
(P ¼ .022) and 1-year graft occlusion of 33% vs 18%
(P ¼ .001). In subsequent analysis of the same database
that also included patients who had bypass procedures for
claudication, Simons et al13 reported a signiﬁcant increase
over time in the proportion of lower extremity bypasses
performed after a previous EVI in patients with CLI
(11%-24%; P < .001) and in claudicant patients (13%-
23%; P ¼ .02). They reported no signiﬁcant change in
the AFS at 1 year in both groups, and major amputation
steadily decreased in CLI patients from 15.4% in 2003 to
11.0% in 2008, whereas graft patency remained similar.
This observation parallels previous observations regarding
the decreasing amputation rates with increased use of
EVI.14 Lastly, there have been some small single-center
series on the use of EVI for treatment of native arterial
occlusions after failure of bypass procedures,15 and the
procedures likely would have been easier had they been
performed initially. These seemingly conﬂicting observa-
tions prompted us to conclude that one has to analyze
the whole cohort of patients with CLI rather than just
a failed subgroup, especially when there is already a selec-
tion bias for either treatment modality.12
Our study reviewed all failures as a group. One of our
main ﬁndings was that the type of failure presentation was
largely affected by the type of the initial presentation.
Patients who initially had CLI were more likely to present
early, more acutely, and with CLI, especially those in the
OR failure group, than the EV group. These groups were
Table VI. The type of all procedures performed in each subgroup after failure
Variable
Overall limbs (N ¼ 347),
No. (%)
DC (n ¼ 66) CLI (n ¼ 171)
OR (n ¼ 23),
No. (%)
EV (n ¼ 43),
No. (%) P
OR (n ¼ 71),
No. (%)
EV (n ¼ 100),
No. (%) P
Bypass/OR 8 (35) 7 (16) .124 23 (32) 3 (3) <.001
41 (17) 15 (21) 26 (15)
Bypass/EV 3 (13) 7 (16) 6 (8) 14 (14)
30 (13) 10 (15) 20 (12)
EV 6 (26) 20 (47) .122 30 (42) 70 (70) <.001
126 (53) 26 (39) 100 (58)
None 6 (26) 9 (21) 12 (17) 13 (13)
40 (17) 15 (23) 25 (15)
CLI, Critical limb ischemia; DC, disabling claudication; EV, endovascular; OR, open revascularization.
Table VII. Effect of initial TransAtlantic Inter-Society
Consensus (TASC) classiﬁcation (A/B vs C/D) on
presentation modes in the endovascular (EV) group
compared with the open revascularization (OR) group in
disabling claudication (DC) and critical limb ischemia
(CLI) groups
Variables EV A/B EV C/D OR
PDC (n ¼ 6), % (n ¼ 37), % (n ¼ 23), %
Asymptomatic 0 5 4 .839
Claudication 83 65 57 .465
Rest pain 17 14 17 .915
Tissue loss 0 3 9 .475
Acute 0 14 9 .568
Bypass 17 35 48 .327
Limb loss 0 0 9 .145
CLI (n ¼ 16) (n ¼ 84) (n ¼ 71)
Asymptomatic 0 7 4 .441
Claudication 6 12 10 .773
Rest pain 0 8 14 .185
Tissue loss 94a 61b 45 .001
Acute 0c 12 23d .038
Bypass 0e 19 44f <.001
Limb loss 25 19 46g .001
aP ¼ .011 vs C/D; P < .001 vs OR.
bP ¼ .052 vs C/D.
cP ¼ .146 vs C/D; P ¼ .036 vs OR.
dP ¼ .078 vs C/D.
eP ¼ .057 vs C/D; P ¼ .001 vs OR.
fP ¼ .001 vs C/D.
gP < .001 vs C/D.
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with mostly multilevel disease and TASC D lesions,
whereas the EV group included more patients with dia-
betes and ischemic ulcers and yet still included 84% with
TASC C and D lesions, achieving patency of the initial
revascularization and overall limb salvage in most patients
with no difference in overall survival. A signiﬁcant number
in whom OR later failed had nonautologous grafts, with
about one-third of the failures occurring early, with the
worst outcomes. The worse overall amputation rate in
the OR CLI group (46%) is also a reﬂection of this group
being the most challenging (Table VII). Nevertheless,these patients were a consecutive patient cohort of failures
and represent the most disadvantaged subgroup of patients
undergoing revascularization.
It is important to note that 70% of EV failures were
managed percutaneously, as were >50% of the patients in
the OR group. The loss of additional runoff vessels is
a risk of any reintervention, whether OR or EV. The
patency rates after secondary bypass procedures in EV
and OR repair groups were comparable, with limb salvage
and patency rates, respectively, of 90% and 81% in the EV
group and 80% and 74% in the OR group. Only one patient
who required amputation had clear embolization of runoff
vessels, and limb loss was related to the initial procedure.
Joels et al3 reviewed the angiograms of patients who
had early failure (mean, 200 days) after superﬁcial femoral
artery interventions retrospectively and determined that the
distal site of bypass was altered theoretically in six limbs
(28%). Only ﬁve patients needed a bypass procedure (1
above the knee, 3 below the knee, and 1 distal), and
none needed an amputation. Although secondary patency
and limb salvage rates were lower in the patients whose
distal sites were changed, these were not statistically signif-
icant, and amputation was rare.
Gur et al1 reported that the failures after stenting of
TASC C and D were more likely to fail with occlusion,
lose runoff vessels, and alter the site of a subsequent OR.
Five of the 10 patients who underwent an OR had an
amputation, all of whom presented with occlusions.
Al-Nouri et al16 reported three major amputations in eight
patients who had failure of stenting of superﬁcial femoral
artery for TASC C or D lesions. In our series, TASC C/D
patients presented more with acute limb-threatening
ischemia and were more likely to be treated with bypass,
which is our general approach in patients who have
TASC D lesions and present with failure. Although
23% had more distal bypasses than they would have
had, none of these patients had an amputation. Only
one patient with TASC D anatomy in this whole series
had an amputation after bypass for failed EVI, which
could be related to the initial procedure. Only two of
the 15 TASC C/D patients with ALI lost their legs,
and these patients initially had CLI and would not
have been candidates for an open bypass.
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nature, involving a population that was 99% male from
a single center. In addition, patients were treated on
a highly individualized basis according to their presenta-
tion, medical condition, ambulatory status, and complexity
of disease, and there was no strict protocol for treatment of
failures.
CONCLUSIONS
The type of clinical presentation after failed revascular-
ization is determined by the initial indication. CLI patients
are more likely to present early and with ALI, especially
after OR. EV reinterventions play a signiﬁcant role in the
management of patients with failed revascularization, and
EV failure is associated with better outcomes than those
after OR failure, likely because OR patients have a more
disadvantaged anatomy and advanced disease at the initial
presentation.
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Table I (online only). The initial revascularization
procedures in open revascularization (OR) and
endovascular (EV) groups for disabling claudication (DC)
and critical limb ischemia (CLI)
Indication No.
DC
OR group 23
Femoropopliteal bypass
Above-knee PTFE 14
Below-knee GSV 3
Below-knee PTFE 3
Femorodistal bypass
GSV 2
Arm vein 1
EV group 43
SFA/popliteal
PTA 4
Stent 31
Plus distal PTA 1
Iliac plus SFA
PTA 1
Stent 6
CLI
OR group 71
Femoropopliteal bypass
Above-knee PTFE 5
Above-knee GSV 2
Below-knee PTFE 11
Below-knee GSV 4
Femorodistal bypass
GSV 21
PTFE 18
Cryopreserved 7
Femoral endarterectomy 3
EV group 100
SFA/popliteal
PTA 4
(With Excimera) (1)
Plus infrapopliteal PTA 6
(With Excimer) (1)
Stent 50
Plus infrapopliteal PTA 5
Plus iliac stent 8
Infrapopliteal
PTA 19
(With Excimer) (4)
(With Foxhollowb) (1)
Plus iliac stent 1
Stent 7
GSV, Great saphenous vein; PTA, percutaneous transluminal angioplasty;
PTFE, polytetraﬂuoroethylene; SFA, superﬁcial femoral artery.
aSpectranetics, Colorado Spings, Colo.
bev3 Endovascular Inc, Plymouth, Minn.
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